The natural history of castration-resistant nonmetastatic prostate cancer is poorly defined. METHODS: The authors used data from 331 subjects in the placebo group of a randomized controlled trial to evaluate the relations of disease and host characteristics with time to first bone metastases in men with prostate cancer, rising prostate-specific antigen (PSA) despite androgen deprivation therapy, and no radiographic evidence of metastases. Relations between baseline covariates and clinical outcomes were assessed by Cox proportional hazard analyses. Covariates in the model were age, body mass index, prior prostatectomy, prior orchiectomy, Gleason score, performance status, PSA, urinary N-telopeptide, bone alkaline phosphatase, albumin, lactate dehydrogenase, and hemoglobin. RESULTS: At 2 years, 46% of subjects had developed bone metastases, and 20% had died. Median bone metastasis-free survival was 25 months. In multivariate analyses, baseline PSA !13.1 ng/mL was associated with shorter overall survival (relative risk [RR], 2.34; 95% confidence interval [CI], 1.71-3.21; P < .0001), time to first bone metastasis (RR, 1.98; 95% CI, 1.43-2.74; P < .0001), and bone metastasis-free survival (RR, 1.98; 95% CI, 1.45-2.70; P < .0001). PSA velocity was significantly associated with overall and bone metastasis-free survival. Other covariates were not consistently associated with clinical outcomes. CONCLUSIONS: In men with progressive castration-resistant prostate cancer and no detectable metastases, baseline PSA was significantly associated with time to first bone metastasis, bone metastasis-free survival, and overall survival. Other disease and host characteristics, including body mass index and bone turnover markers, were not consistently associated with clinical outcomes. Cancer
Obesity has been implicated in worse prostate cancer outcomes for men with early stage disease. Greater BMI is associated with higher-grade prostate cancer and higher rates of PSA recurrence after prostatectomy. 5, 6 Greater BMI is associated with higher rates of PSA failure after radiation therapy 7 and shorter survival after combined modality therapy for locally advanced prostate cancer. 8 The relations between BMI and clinical outcomes in men with castration-resistant nonmetastatic disease are undefined.
Biochemical markers of osteoblast and osteoclast activity are markedly elevated in men with metastatic prostate cancer, and levels correspond to extent of skeletal involvement. 9, 10 In men with metastatic disease, elevated serum levels of total or bone-specific alkaline phosphatase are independently associated with shorter survival. [11] [12] [13] In men without bone metastases, ADT significantly increases biochemical markers of osteoblast and osteoclast activity, including serum bone-specific alkaline phosphatase (BAP) and urinary excretion of N-telopeptide (NTx). 14 Preclinical studies suggest that the microenvironment of actively remodeling bone contributes to the preferential spread of prostate cancer to bone, 15 although the relation between biochemical markers of bone turnover and risk for bone metastases is undefined in humans.
We used data from the placebo group of a previously reported international randomized controlled trial of atrasentan 16 to investigate the relations between disease and host characteristics, including BMI and biochemical markers of bone turnover, and time to first bone metastases and death in men with castration-resistant prostate cancer and no radiographically detectable metastases.
MATERIALS AND METHODS
As previously reported, Abbott M00-244 was a randomized, double-blind, placebo-controlled study to evaluate the effects of atrasentan on time to disease progression in men with progressive castration-resistant prostate cancer and no radiographic evidence of bone metastases. 16 A total of 941 subjects were enrolled in the study between July 2001 and April 2003; 467 subjects were assigned to atrasentan, and 474 subjects were assigned to placebo. The current analyses evaluate the 331 subjects from the placebo group with complete baseline data.
Subjects
All subjects had prostate cancer and had undergone ADT (bilateral orchiectomy or medical castration) at least 3 months before randomization, and had castrate testosterone levels at screening. Before randomization, PSA levels were at least 20 ng/mL within 12 months, had increased by 50% within 6 months (minimum PSA 1 ng/mL at screening), or were rising (2 sequential increases with third confirmatory rise; minimum PSA 1 ng/mL at screening) within 12 months. No subject had radiographic evidence of metastases at study entry. Subjects were also excluded if they had received prior chemotherapy, bisphosphonates, radiopharmaceuticals, or an endothelin receptor antagonist. Subjects with current cardiovascular disability (New York Heart Association Class 2 or greater) were also excluded. The institutional review board or independent ethics committee at each participating site approved the protocol. Each subject gave written informed consent.
Study Design
Before randomization, subjects underwent screening evaluations for eligibility, including bone scan and chest, abdomen, and pelvic computed tomography scans or magnetic resonance imaging scans. Absence of metastatic disease was confirmed by central independent review.
Eligible subjects were assigned randomly in a 1:1 ratio to atrasentan (10 mg by mouth daily) or matching placebo. Subjects continued ADT throughout the study. Other therapies (except for continued ADT with a gonadotropin-releasing hormone agonist) were prohibited on study. During double-blind treatment, subjects were evaluated at Day 14; Weeks 4, 8, and 12; and every 6 weeks thereafter. PSA and bone turnover markers were measured at Weeks 4, 8, and 12, and every 12 weeks thereafter. Bone scans were performed every 12 weeks and underwent centralized independent review to assess disease progression. Study treatment continued until confirmed disease progression, unacceptable adverse effects, subject withdrawal, or study completion.
Outcomes
The main outcomes considered in these analyses were time from first dose after randomization to first documentation of bone metastasis, overall survival, and bone metastasis-free survival.
Statistical Analyses
The time to first bone metastasis was defined as the time from first dose after randomization to first positive bone scan. Subjects not observed to develop bone metastases were censored at the last available evaluation or last date of an unconfirmed report of disease progression. Univariate cause-specific Cox regression models were fit for the time to first bone metastasis using each covariate as a single explanatory variable. 17 Next, multivariate models were fit using all explanatory variables to identify those that were independently predictive. Stepwise backward elimination was performed to determine the simplest multivariate model. Tests for the validity of the proportional hazards assumption were also performed. 18 If there was evidence of violations to this assumption, models were expanded to allow relative risks to vary with time.
Cox regression analyses were also conducted for the survival time, defined as the number of days from first dose after randomization to death, or the time from first dose after randomization to last contact for those not observed to die, with the latter again being treated as right censoring times. Cox models for bone metastases-free survival were fit in a similar way. Here, however, the censoring time was the minimum censoring time for bone metastases (end of the double-blind follow-up phase) and the censoring time for death (last contact). Cumulative incidence plots were created to characterize the proportion of subjects having experienced at least 1 new bone metastasis; Kaplan-Meier estimates were plotted for the survival distribution and for the bone-metastases free survival analyses.
The covariates considered in Cox regression analyses included baseline age, BMI (<25 kg/m 2 , 25-29.9 kg/m 2 , vs !30 kg/m 2 ), prior prostatectomy (yes vs no), prior orchiectomy (yes vs no), Gleason sum (!7 vs <7), Eastern Cooperative Oncology Group performance status ( 80 vs 90-100), PSA (!13.1 ng/mL vs <13.1 ng/mL), NTx (! 13.6 nmol bone collagen equivalent [BCE]/L vs <13.6 nmol BCE/L), BAP (! 13.2 ng/mL vs <13.2 ng/ mL), albumin, lactate dehydrogenase, and hemoglobin.
PSA velocity was defined as the slope of regression line of natural log PSA by time over the first 12 weeks of follow-up. Specifically, a linear model was fit to log PSA values at baseline assessment, 4 weeks, 8 weeks, and 12 weeks versus time. Subjects without at least 2 PSA assessments were excluded from analyses involving PSA velocity. If a baseline assessment was not available, PSA value at screening assessment was used.
In Cox regression analyses described above, some clinical events (development of bone metastases, for example) may have occurred during the assessment of PSA velocity. To account for temporal ordering of PSA data and clinical events, additional Cox regression analyses were conducted. In this second set of analyses, subjects were not considered at risk for clinical events until week 12. Data from the first 12 weeks were used to compute the PSA velocity, but no events were counted in this period. Although this excludes some clinical events, it ensures a temporal ordering of the PSA data and the subsequent clinical events.
RESULTS

Baseline Characteristics
Baseline prostate cancer and subject characteristics are summarized in Table 1 . Mean age was 73 AE 8 years. Ninety-five percent of men were white. Median BMI was 27.8 kg/m 2 . By National Institutes of Health classification, 20.8% men were normal (BMI <25 kg/m 2 ), 47.6% were overweight (BMI 25-29.9 kg/m 2 ), and 31.6% were obese (BMI !30 kg/m 2 ). Seventy-one percent of men had Gleason sum !7. Seventeen percent had a prior prostatectomy; 30.2% had prior orchiectomy. Median serum PSA at study entry was 13.1 ng/mL. Figure 1A provides a cumulative incidence plot for the proportion of subjects with at least 1 bone metastasis and Kaplan-Meier plots for the proportion of subjects who have died (Fig. 1B) and the proportion of subjects experiencing bone metastasis or death (Fig. 1C) . At 2 years, 46% of subjects had developed at least 1 bone metastasis, and 20% had died. Median bone metastasis-free survival was 25 months.
Time to First Bone Metastasis and Survival
Cox Regression Analyses
Time to first bone metastasis In univariate analyses (Table 2) , baseline PSA !median value of 13.1 ng/mL was associated with shorter time to first bone metastases (relative risk, 2.02; 95% confidence interval [CI], 1.46-2.80; P < .001). Prior prostatectomy was also associated with shorter time to first bone metastasis (relative risk, 1.51; 95% CI, 1.00-2.28; P ¼ .048). Older age was associated with longer time to first bone metastasis (relative risk, 0.95 for each additional year of age; 95% CI, 0.93-0.97; P < .001). Other host covariates including BMI and biochemical markers of bone turnover were not associated with time to first bone metastasis.
Baseline PSA and age remained statistically significant in full and reduced multivariate Cox regression models with relative risks of 1.98 (95% CI, 1.43-2.74; P < .001) and 0.95 (95% CI, 0.93-0.97; P < .001), respectively ( Table 2) . Prior prostatectomy was not statistically significant in multivariate models. In Cox regression models that were expanded to allow relative risks to vary with time, the relative risk for elevated baseline PSA (!13.1 ng/mL) over the first year was 2.96 (95% CI, 1.80-4.87; P < .001), and it was 1.36 (95% CI, 0.85-2.16; P ¼ .196) during the second and subsequent years.
Overall survival
In univariate analyses (Table 3) , baseline PSA !median value (relative risk, 2.36; 95% CI, 1.72-3.23; P < .001) and baseline NTx !median value (relative risk, 1.39; 95% CI, 1.03-1.88; P ¼ .031) were significantly associated with shorter survival (Table 3) . Baseline serum albumin (relative risk, 0.46 for each 1 g/dL increase; 95% CI, 0.28-0.77; P ¼ .003) and hemoglobin (relative risk, 0.86 for each 1 g/dL increase; 95% CI, 0.75-0.99; P ¼ .042) were significantly associated with longer survival. In multivariate Cox regression analyses, PSA, NTx, and albumin were significantly associated with overall survival (Table 3 ). In the reduced model, relative risks for PSA, NTx, and albumin were 2.34 (95% CI, 1.71-3.21; P < .001), 1.41 (95% CI, 1.05-1.91; P ¼ .025), and 0.50 for each 1 g/dL increase (95% CI, 0.30-0.83; P ¼ .007), respectively.
In Cox regression models that were expanded to allow relative risks to vary with time, relative risk for elevated baseline PSA was 3.17 (95% CI, 2.09-4.82; P < .001) for the first 3 years and 1.44 (95% CI, 0.87-2.39; P ¼ .156) for subsequent years.
Bone metastases-free survival
In univariate analyses (Table 4) , baseline PSA !median value (relative risk, 2.02; 95% CI, 1.48-2.76; P < .001) and prior prostatectomy (relative risk, 1.49; 95% CI, 1.01-2.19; P ¼ .046) were associated with shorter bone metastasis-free survival. Older age was associated with longer bone metastasis-free survival (relative risk, 0.96 for each additional year of age; 95% CI, 0.94-0.98; P < .001).
Baseline PSA and age remained statistically significant in full and reduced multivariate Cox regression models, with relative risks of 1.98 (95% CI, 1.45-2.70; P < .001) and 0.96 (95% CI, 0.94-0.99; P<.001), respectively. Similar to multivariate analyses for other outcomes, prior prostatectomy was not significantly associated with bone metastasis-free survival. Again, however, there was evidence of a time-varying effect of elevated baseline PSA. The relative risk for elevated baseline PSA was 3.11 (95% CI, 1.92-5.04; P < .001) during the first year and 1.33 (95% CI, 0.86-2.06; P ¼ .196) for subsequent years.
Additional analyses were conducted including covariates reflecting changes in PSA and bone metabolism markers from baseline to Week 12. After controlling for other covariates, higher PSA velocity was significantly Figure 2B illustrates the estimated survival distribution for bone metastases or death by tertiles of PSA velocity.
DISCUSSION
By using data from an international randomized controlled trial, we observed that men with progressive castration-resistant nonmetastatic prostate cancer have a relatively indolent clinical course. Forty-six percent of men developed bone metastases at 2 years, and median metastasis-free survival was 25 months. Higher baseline PSA was significantly associated with shorter time to first bone metastasis, overall survival, and bone metastasis-free survival. PSA velocity was associated with shorter overall and bone metastasis-free survival. No other cancer covariate and none of the host covariates, including BMI and bone turnover markers, was consistently associated with clinical outcomes.
Our results are consistent with an earlier report of an aborted randomized controlled trial of zoledronic acid to prevent bone metastases in men with progressive castration-resistant nonmetastatic prostate cancer. In analyses of 201 subjects assigned to a placebo group, 1 = 3 of men developed bone metastases after 2 years, and median bone metastasis-free survival was 30 months. 4 Higher baseline PSA and PSA velocity were associated with time to first bone metastasis and survival. Other covariates were not Gleason score <7
Gleason score ‡7 associated with clinical outcomes. Notably, the study lacked information about host characteristics, including BMI and biochemical markers of bone turnover. These results extend the evidence linking PSA kinetics to clinical outcomes. In men with rising PSA after surgery or radiation therapy for early stage disease, greater PSA velocity is associated with shorter time to metastases [19] [20] [21] [22] and survival. [23] [24] [25] PSA velocity is also associated with survival in men with castration-resistant metastatic prostate cancer. 26 Prevention of bone metastases remains a major unmet medical need in men with prostate cancer. Failure of prior metastasis prevention studies in men with castration-resistant nonmetastatic prostate cancer may reflect, at least in part, the lower than expected event rates in this disease state. The consistent observations that PSA and PSA velocity were associated with shorter time to first bone metastasis, however, may inform the design of clinical trials to prevent bone metastases in men with castration-resistant disease. The predictive value of PSA and PSA velocity suggests that PSA and PSA kinetics might provide a convenient and effective strategy to identify men at high risk for bone metastases or death. An ongoing global phase 3 study of denosumab to prevent bone metastases in men with castration-resistant prostate cancer (NCT00286091) includes only subjects with PSA !8 ng/ mL or PSA doubling time 10 months. Event rates of subjects in the placebo group of this study may validate use of PSA and PSA kinetics for selection of high-risk subjects in this setting.
To the best of our knowledge, these analyses are the first to evaluate the relation between bone turnover markers and subsequent bone metastases using a large prospective database. In men with metastatic prostate cancer, biochemical markers of osteoblast and osteoclast activity are elevated, and levels correspond to extent of skeletal involvement. 9, 10 In cross-sectional studies, a variety of bone-specific markers, including BAP and urinary , test of homogeneity, P value; BMI, body mass index; KPS, Karnofsky performance score; PSA, prostate-specific antigen; Ntx, serum N-telopeptides; BAP, bone alkaline phosphatase; LDH, lactate dehydrogenase; HGB, hemoglobin. All models stratified by cancer duration <7 years or !7 years.
NTx, are associated with radiographically detectable bone metastases. 27 Despite careful prospective ascertainment of new bone metastases, absence of potentially confounding effects of other systemic therapies, and a large number of informative events, we found no significant association between baseline BAP or urinary NTx and time to first bone metastases or bone metastasis-free survival. Addition studies of other markers and/or higher risk patients are needed.
Greater BMI is associated with higher rates of PSA failure after surgery or radiation therapy for early stage prostate cancer. [5] [6] [7] Greater BMI is also associated with shorter survival after combined modality therapy for locally advanced disease. 8 Several mechanisms have been proposed to explain worse clinical outcomes for obese men after primary treatment for locoregional disease. These putative mechanisms include changes in gonadal steroids, increased insulin and insulin-like growth factors, alterations in adipocytokines, understaging, decreased local control, and decreased effectiveness of ADT. 28 In contrast to reports in earlier stage disease, obesity was not associated with clinical outcomes in our subjects. If confirmed in other studies, the absence of a relation between BMI and clinical outcomes in castration-resistant disease may help define mechanisms responsible for higher rates of failure in overweight and obese men after primary treatment for early stage prostate cancer.
These analyses have several strengths. The study was large, including subjects from 183 sites in the United States and Europe. Bone scans were performed every 12 weeks, and all imaging studies underwent independent central review. Any potential ascertainment bias for new bone metastases (including possible bias introduced by rising PSA) was minimized by the frequent schedule for bone scans. In contrast to the study of zoledronic acid in this setting, treatment with 
